M&T Bank Corp Grows Stock Position in Becton, Dickinson and Company (NYSE:BDX)

M&T Bank Corp grew its position in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 18.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 75,537 shares of the medical instruments supplier’s stock after buying an additional 11,895 shares during the quarter. M&T Bank Corp’s holdings in Becton, Dickinson and were worth $20,092,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BDX. Smith Shellnut Wilson LLC ADV boosted its holdings in shares of Becton, Dickinson and by 3.2% during the fourth quarter. Smith Shellnut Wilson LLC ADV now owns 1,224 shares of the medical instruments supplier’s stock worth $308,000 after purchasing an additional 38 shares during the last quarter. Somerset Trust Co boosted its holdings in shares of Becton, Dickinson and by 0.3% during the first quarter. Somerset Trust Co now owns 14,459 shares of the medical instruments supplier’s stock worth $3,846,000 after purchasing an additional 39 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. boosted its holdings in shares of Becton, Dickinson and by 1.1% during the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,765 shares of the medical instruments supplier’s stock worth $947,000 after purchasing an additional 40 shares during the last quarter. First Citizens Bank & Trust Co. boosted its holdings in shares of Becton, Dickinson and by 4.1% during the fourth quarter. First Citizens Bank & Trust Co. now owns 1,016 shares of the medical instruments supplier’s stock worth $255,000 after purchasing an additional 40 shares during the last quarter. Finally, Blossom Wealth Management boosted its holdings in Becton, Dickinson and by 3.5% in the first quarter. Blossom Wealth Management now owns 1,192 shares of the medical instruments supplier’s stock valued at $317,000 after acquiring an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 86.58% of the company’s stock.

Becton, Dickinson and Stock Up 0.7 %

Shares of NYSE BDX opened at $254.23 on Friday. Becton, Dickinson and Company has a 1 year low of $231.46 and a 1 year high of $280.62. The firm has a market cap of $72.47 billion, a price-to-earnings ratio of 43.83, a PEG ratio of 3.41 and a beta of 0.59. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.35. The stock’s 50-day simple moving average is $244.97 and its 200-day simple moving average is $256.22.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The business had revenue of $4.64 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same period in the previous year, the company earned $2.74 earnings per share. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 11.18 earnings per share for the current fiscal year.

Becton, Dickinson and Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be paid a $0.87 dividend. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a yield of 1.37%. Becton, Dickinson and’s dividend payout ratio (DPR) is 60.00%.

Insider Buying and Selling

In related news, VP Thomas J. Spoerel sold 443 shares of Becton, Dickinson and stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total value of $115,180.00. Following the completion of the transaction, the vice president now directly owns 1,058 shares in the company, valued at $275,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BDX. Piper Sandler reduced their target price on Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday, May 5th. StockNews.com upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Wednesday. Morgan Stanley reduced their target price on Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating on the stock in a report on Friday, July 15th. Citigroup cut Becton, Dickinson and from a “neutral” rating to a “sell” rating and reduced their target price for the company from $265.00 to $235.00 in a report on Monday, July 11th. Finally, Stifel Nicolaus reduced their target price on Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and has an average rating of “Hold” and an average target price of $270.88.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.